Navigation Links
Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
Date:2/20/2008

BEDFORD, Mass., Feb. 20 /PRNewswire-FirstCall/ -- Insulet Corporation, (Nasdaq: PODD), the leader in wearable insulin pump technology with its OmniPod(R) Insulin Management System, announced plans to release its financial results for the fourth quarter and full year 2007 on Monday, March 17, 2008 after the close of the financial markets.

Insulet will also host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 18, 2008 to discuss its fourth quarter and full year 2007 financial results. During the conference call, material information concerning the Company, its operations, strategies and prospects may be discussed.

To listen to the conference call, please dial 866.314.5232 for domestic callers and 617.213.8052 for international callers. The passcode is 86189075. A replay of the conference call will be available two hours after the start of the call through April 18, 2008 by dialing 888-286-8010 (domestic) and 617-801-6888 (international), passcode 17622814. An online archive of the conference call will also be available by accessing the Investor Information section of the company's website at http://investors.insulet.com.

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000,
'/>"/>

SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
2. Pharmion Corporation Announces 2007 Operating Results
3. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
4. VLST Corporation Announces Board and Executive Management Appointments
5. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
8. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
9. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
10. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
11. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
(Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from clinical ... key industry events beginning with Patient-Centered Clinical Trials 2014 ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits ... variety of tactics – from media to mobile apps – ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2
... N.J., Nov. 10 Aton Pharma, Inc., ... a recent,survey of ophthalmologists regarding issues in ... dry eye. Aton provides the dry eye ... sustained release prescription insert that helps to ...
... - Seventh Study Showing Oncotype DX Frequently Changes Treatment ... Recommendations in Clinical Practice -, ... GHDX ) today announced the publication of results from ... way,physicians treat early-stage breast cancer. The study, published in the,October ...
... China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq:,SSRX), ... and marketing biopharmaceutical products primarily in China,today announced ... Food and Drug,Administration (SFDA) for approval of NuLeusin ... carcinoma. If approved, NuLeusin is expected to,be the ...
Cached Biology Technology:Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 3Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 4Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 5Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 2Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 3Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 43SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4
(Date:8/28/2014)... marine protected areas is needed to protect fish species ... from the Wildlife Conservation Society and other organizations, previous ... largest numbers of species, often at the expense of ... , Many vital ecological functions of ocean ... food for millions of people. This study uncovers ...
(Date:8/28/2014)... researcher and his collaborators have developed an online analytic ... of re-engineering cells for biomedical investigation. CellNet is a ... aid stem cell engineering. Details of CellNet and its ... back-to-back papers in the journal Cell . , ... for all types of cell-based investigations and can potentially ...
(Date:8/28/2014)... have identified the developmental on-off switch for Streptomyces ... than two-thirds of the world,s naturally derived antibiotic medicines. ... whether it is possible to manipulate this switch to ... study, appearing August 28 in Cell , found ... cyclic-di-GMP and a larger protein called BldD ultimately controls ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... the red flour beetle living happily in the flour sack ... University, and many others throughout the world, this pest of ... studying genetics. The superior status of this beetle, Tribolium ... work of two Kansas State University faculty, Susan Brown, professor ...
... League Baseball pitchers indicates that the height of the pitchers ... lead to potential injuries because of stress on the shoulder ... William Raasch, M.D., associate professor of orthopaedic surgery at the ... head team physician for the Milwaukee Brewers. Major League Baseball ...
... Mich. Michigan State University scientist Ned Walker is taking ... he believes he can help win the battle to save ... million grant from the National Science Foundation, Walker will lead ... the population dynamics of the parasite that causes the deadly ...
Cached Biology News:Study finds pitching mound height affects throwing motion, injury risk 2Netting mosquitoes to prevent malaria 2
... microplate coating using advanced automated high throughput microplate processing equipment ... can also accommodate virtually any lot size of the following ... 8 and 12 well strips, ... 384 well microplate, ...
... first biological reagent that eliminates ... not just by inhibiting growth. ... agent that can be used ... The cytotoxicity of Mynox is ...
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
A trigger solution for Flashlight labeled materials....
Biology Products: